The search for novel antiarrhythmic strategies

European Heart Journal

Volumn 19, Issue 8, 1998, Pages 1178-1196

  Hoffman, Brian F ^c   Janse, Michiel J ^c   Kléber, André ^c   Schwartz, Peter J ^c   Woosley, Raymond L ^c   Anderson, Jeffrey L ^c   Breithardt, Günter ^c   Campbell, Ronald W F ^c   Hallstrom, Alfred P ^c   Hiraoka, Masayasu ^c   Myerburg, Robert J ^c   Ogawa, Satoshi ^c   Pratt, Craig M ^c   Roden, Dan M ^c   Ruskin, Jeremy N ^c   Spooner, Peter M ^c   Temple, Robert J ^c   Waldo, Albertl ^c   Wood, Alastair J J ^c   Zaza, Antonio ^c   Boyden, Penelope ^c   Lazzara, Ralph ^c   Zipes, Douglas P ^c   Camm, A John ^b   Rosen, Michael R ^a   more..

^a Department of Pharmacology ^*  (United States)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c NONE

Author keywords

Arrhythmogenic substrates; Atrial fibrillation; Clinical trials; Congenital long QT syndrome; Targeted antiarrhythmic therapy; Triggering factors for antiarrhythmias; Ventricular tachycardia and fibrillation

Indexed keywords

ANTIARRHYTHMIC AGENT;

HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; LONG QT SYNDROME; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; SUDDEN DEATH;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; ATRIAL FIBRILLATION; CLINICAL TRIALS; HUMANS; LONG QT SYNDROME; TACHYCARDIA, VENTRICULAR;

EID: 0032147084     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1998.1081     Document Type: Review

References (160)

1. [1] Task Force of the Working Group on Arrhythmics of the European Society of Cardiology: The Sicilian Gambit. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Circulation 1991; 84: 1831-51.
2. [2] Task Force of the Working Group on Arrhythmics of the European Society of Cardiology: The Sicilian Gambit. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Eur Heart J 1991; 12: 1112-31.
3. [3] Members of the Sicilian Gambit. Antiarrhythmic Therapy: A Pathophysiologic Approach. Armonk, NY: Futura Publishing Company, 1994.
4. [4] Waldo AL, Camm AJ, Deruyter H et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996; 348: 7-12.
5. [5] Cairns JA, Connolly SJ, Roberts R, Gent M and the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet 1997; 349: 675-82.
6. [6] Julian DG, Camm AJ, Frangin G et al. and the European Myocardial Infarct Amiodarone Trial Investigators. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997; 349: 667-74.
7. [7] Singh SN, Fletcher RD, Fisher SG et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure.. N Engl J Med 1995; 333: 77-82.
8. [8] Scherf D, Schott A. Extrasystoles and Allied Arrhythmias. Chicago, IL: Yearbook Medical Publishers, 1973.
9. [9] Mautz FR. Reduction of cardiac irritability by epicardial and systemic administration of drugs as protection in cardiac surgery. J Thorac Surg 1936; 5: 612.
10. [10] Frey W. Über Vorhofflimern beim Menschen und seine Beseitigung durch Chiniden. Berl klin Wschr 1918; 55: 417-50.
11. [11] Mark LC, Kayden JJ, Steele JM et al. The physiological disposition and cardiac effects of procaine-amide. J Pharmacol Exp Ther 1951; 102: 5-15.
12. [12] Hondeghem LM. Class III agents: amiodarone, bretylium and sotalol. In: Zipes D, Jalife J, eds. Cardiac Electrophysiology: From Cell to Bedside. Philadelphia, PA: WB Saunders Co, 1995: 1330-5.
13. [13] McFarlane P, Lawrie TDV. Comprehensive Electrocardiology: Theory and Practice in Health and Disease, Vol. 3. Oxford, England: Pergamon Press, 1989.
14. [14] Rosenbaum MB, Blanco HH, Elizari MV, Lazzari JQ, Davidenko J. Electronic modulation of the T wave and cardiac memory. Am J Cardiol 1982; 50: 213-22.
15. [15] Chatterjee K, Harris A, Davies G, Leatham A. Electrocardiographic changes subsequent to artificial ventricular depolarization. Br Heart J 1969; 31: 770-9.
16. [16] Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995; 92: 1954-68.
17. [17] Ziegler RF. Patent ductus arteriosus. In: Moss AJ, Adams FH, eds. Heart disease in infants, children and adolescents. Baltimore, MD: Williams and Wilkins Co, 1998: 338-57.
18. [18] Boyden PA, Jeck CD. Ion channel function in disease. Cardiovasc Res 1995; 29: 312-18.
19. [19] Hondeghem L. Ideal antiarrhythmic agents: chemical defibrillators. J Cardiovasc Electrophysiol 1991; 2 (Suppl): S169-S177.
20. [20] Gintant GA. Two components of delayed rectifier current in canine atrium and ventricle. Circ Res 1996; 78: 26-37.
21. ks) in a canine epicardial, midmyocardial and endocardial myocytes. Circ Res 1995; 76: 351-65.
22. ks function. Nature Genetics 1997; 17: 338-340.
23. [23] Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995; 80: 795-80.
24. kr potassium channel. Cell 1995; 81: 299-307.
25. + channel dysfunction in an inherited cardiac arrhythmia. Proc Natl Acad Sci 1996a; 93: 2208-12.
26. Ks potassium channel. Nature 1996; 384: 80-3.
27. [27] Wang Q, Shen J, Li Z et al. Cardiac sodium channel mutations in patients with long QT syndrome, an inherited cardiac arrhythmia. Hum Molec Gen 1995; 4: 1603-7.
28. [28] Wang Q, Shen J, Splawski I, Atkinson D, Li Z. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell 1995; 80: 805-11.
29. [29] Wang Q, Curran ME, Splawski I et al. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nature Genetics 1996; 12: 17-23.
30. [30] Schott JJ, Charpentier F, Peltier S et al. Mapping of a gene for long QT syndrome to chromosome 4q25-27. Am J Hum Genet 1995; 57: 1114-22.
31. [31] Roden DM, Lazzara R, Rosen M, Schwartz P, Towbin J, Vincent GM. Multiple mechanisms in the long-QT syndrome: Current knowledge, gaps, and future directions. Circulation 1996; 94: 1996-2012.
32. [32] Schwartz PJ. The long QT syndrome - clinical approaches to tachyarrhythmias series. Camm AJ, ed. Armonk, NY: Futura Publishing Co, 1997: 1-108.
33. + channel mutations in Romano-Ward and Jervell and Lange-Nielsen inherited cardiac arrhythmias. EMBO 1997; 16: 5472-9.
34. [34] Shalaby FY, Levesque PC, Yang W-P et al Dominant-negative KvLQT1 mutations underlie the LQT1 form of long QT syndrome. Circulation 1997; 96: 1733-6.
35. [35] Bennett PB, Yazawa K, Makita N, George Jr AL. Molecular mechanism for an inherited cardiac arrhythmia. Nature 1995; 376: 683-5.
36. [36] Dumaine R, Wang Q, Keating MT et al. Multiple mechanisms of sodium channel-linked long QT syndrome. Circ Res 1996; 78: 916-24.
37. + in canine and guinea pig Purkinje fibers. J Cardiovasc Electrophysiol 1995; 6: 796-812.
38. 2+ current. Circ Res 1989; 64: 977-90.
39. [39] Brachmann J, Scherlag BJ, Rosenshtraukh LV, Lazzara R. Bradycardia-dependent triggered activity: Relevance to drug induced multiform ventricular tachycardia. Circulation 1983; 68: 846-56.
40. + channel blockade and to increases in heart rate: Implications for gene-specific therapy. Circulation 1995; 92: 3381-6.
41. + channels. Circ Res 1996; 79: 103-8.
42. c responses to mexiletine and to heart rate changes differentiate LQT1 from LQT3 but not from LQT2 patients (Abstr). Circulation 1996; 94 (Suppl): I-204.
43. + currents. Pflügers Arch 1992; 420: 180-6.
44. + current in cardiac cells. Circ Res 1997; 80: 782-9.
45. [45] Compton SJ, Lux RL, Ramsey MR et al. Genetically defined therapy of inherited long-QT syndrome. Correction of abnormal repolarization by potassium. Circulation 1996; 94: 1018-22.
46. [46] McAllister RE, Noble D. The time and voltage dependence of the slow outward current in cardiac Purkinje fibres. J Physiology 1996; 186: 632-62.
47. [47] Choy AM, Lang CC, Chomsky DM, Rayos GH, Wilson JR, Roden DM. Normalization of acquired QT prolongation in humans by IV potassium. Circulation 1997; 96: 2149-54.
48. [48] Wang DW, Yazawa K, Makita N, George Jr AL, Bennett PB. Pharmacological targeting of long QT mutant sodium channels. J Clin Invest 1997; 99: 1714-20.
49. [49] Schwartz PJ. Idiopathic long QT syndrome: progress and questions. Am Heart J 1985; 109: 399-411.
50. [50] Schwartz PJ, Priori SG. Sympathetic nervous system and cardiac arrhythmias. In: Zipes DP, Jalife J, eds. Cardiac Electrophysiology. From Cell to Bedside. Philadelphia, PA: WB Saunders Co, 1990: 330-43.
51. [51] Bliddal J. Familial atrial fibrillation and otosclerosis. In: Sandøe E, Flensted-Jensen E, Olesen K, eds. Symposium On Cardiac Arrhythmias. Sweden: AB Astra, Södertälje, 1970: 109-25.
52. [52] Brugada R, Tapscott T, Czernuszewicz GZ et al. Identification of a genetic locus for familial atrial fibrillation. N Engl J Med 1997; 336: 905-11.
53. [53] Falk RH. Control of the ventricular rate in atrial fibrillation. In: Falk RH, Podrid PJ, eds. Atrial fibrillation: Mechanisms and Management. New York, NY: Raven Press, 1992: 255-82.
54. [54] Nattel S, Wang Z, Pelletier LC, Carrier M, Meere C, Cartier R. Termination of atrial fibrillation by drugs. In Allessie MA, Fromer M, eds. Atrial and Ventricular Fibrillation: Mechanisms and Device Therapy. Armonk, NY: Futura Publishing Company, 1997: 199-214.
55. [55] Van Gelder IC, Crijns HJ, Van Gilst WH, Verwer R, Lie KI. Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter. Am J Cardiol 1991; 68: 41-46.
56. [56] Allessie MA, Lammers WJEP, Bonke FIM, Hollen J. Experimental evaluation of Moe's multiple wavelet of atrial fibrillation. In: Zipes DP, Jalife, J, eds. Cardiac Electrophysiology and Arrhythmias. Orlando, FL: Grune & Stratton, 1985: 265-76.
57. [57] Schuessler RB, Grayson TM, Bromberg BI, Cox JL, Boineau JP. Cholinergically mediated tachyarrhythmias induced by a single extrastimulus in the isolated canine right atrium. Circ Res 1992; 71: 1254-76.
58. [58] Waldo AL, Cooper TB. Spontaneous onset of type I atrial flutter in patients. J Am Coll Cardiol 1996; 28: 707-12.
59. [59] Jais P, Haissaguerre M, Shah DC et al. A focal source of atrial fibrillation treated by discrete radiofrequency ablation. Circulation 1997; 95: 572-6.
60. [60] Cox JL, Canavan TE, Schuessler RB, Cain ME, Lindsay BD, Stone C. The surgical treatment of atrial fibrillation. II: Intraoperative electrophysiologic mapping and description of the electrophysiologic basis of atrial flutter and atrial fibrillation. J Thorac Cardiovasc Surg 1991; 101: 406-26.
61. [61] Cox JL, Schuessler RB, D'Agostino HJ et al. The surgical treatment of atrial fibrillation. III: Development of a definitive surgical procedure. J Thorac Cardiovasc Surg 1991b; 101: 569-83.
62. [62] Kouings KTS, Kirchof CJHJ, Smeets JRLM, Wellens HJJ, Penn OC, Allessie MA. High-density mapping of electrically induced atrial fibrillation in humans. Circulation 1994; 89: 1665-80.
63. [63] Kumagai K, Khrestian C, Waldo AL. Simultaneous multisite mapping during induced atrial fibrillation in the sterile pericarditis model: Insights into the mechanism of its maintenance. Circulation 1997; 95: 511-21.
64. [64] Haissaguerre M, Gencel L, Fisher B et al. Successful catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol 1994; 5: 1045-52.
65. [65] Swartz JF, Pellerseis G, Silvers J, Patten L, Cervantez D. A catheter-based curative approach to atrial fibrillation in humans (Abstr). Circulation 1994; 90 (pt 2): I-355.
66. [66] Elvan A, Pride HP, Eble JN, Zipes DP. Radiofrequency catheter ablation of the atria reduces the inducibility and duration of atrial fibrillation in dogs. Circulation 1995; 91: 2235-44.
67. [67] Haissaguerre M, Jais P, Shah DC et al. Right and left atrial radiofrequency catheter therapy of paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol 1996; 7: 1132-44.
68. [68] Attuel P, Childers R, Cauchemex B, Poveda J, Mugica J, Coumel P. Failure in the rate adaptation of the atrial refractory period: its relationship to vulnerability. Int J Cardiol 1982; 2: 179-97.
69. [69] Boutjdir M, Le Heuzey JY, Lavergne T et al. Inhomogeneity of cellular refractoriness in human atrium: factor of arrhythmia? PACE 1986; 9: 1095-1100.
70. [70] Ramdat Misier AR, Opthof T, van Hemel NM et al. Increased dispersion of 'refractoriness' in patients with idiopathic paroxysmal atrial fibrillation. J Am Coll Cardiol 1992; 19: 1531-5.
71. [71] Daoud EG, Begun F, Goyal R et al. Effect of atrial fibrillation on atrial refractoriness in humans. Circulation 1996; 94: 1600-6.
72. [72] Le Grand B, Hatem SD, Deroubaix E, Couétil JP, Coraboeuf E. Depressed transient outward and calcium currents in dilated human atria. Cardiovasc Res 1994; 28: 548-56.
73. [73] Wijffels MCEF. Atrial fibrillation begets atrial fibrillation. Thesis, University of Maastricht, 1996. Universitaire Pers, Maastricht.
74. [74] Goette A, Honeycutt C, Langberg JJ. Electrical remodeling in atrial fibrillation. Circulation 1996; 94: 2968-74.
75. + Current Densities and Kv1.5 Expression are Reduced in Chronic Human Atrial Fibrillation. Circ Res 1997; 80: 772-81.
76. [76] Mary-Rabine L, Albert A, Pham TD et al. The relationship of human atrial cellular electrophysiology to clinical function and ultrastructure. Circ Res 1983; 52: 188-99.
77. [77] Coumel P. Neural aspects of paroxysmal atrial fibrillation. In: Falk RH, Podrid PJ, Eds. Atrial Fibrillation: Mechanisms and Management. New York: Raven Press Ltd, 1992: 109\\20525.
78. [78] The Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials [published erratum appears in].Arch Intern Med 1994; 154: 1449-57.
79. [79] Daubert C, Mabo P, Berder V, Gras D, Leclercq C. Atrial tachyarrhythmias associated with high degree interatrial conduction block: prevention by permanent atrial resynchronization. Eur J Cardiac Pacing Electrophysiol 1994; 4: 35-44.
80. [80] Saksena S, Prakash A, Hill M et al. Prevention of recurrent atrial fibrillation with chronic dual-site right atrial pacing. J Am Coll Cardiol 1996; 28: 687-94.
81. [81] Levy S, Morady F. A randomized comparison of external and internal cardioversion of chronic atrial fibrillation [letter]. Circulation 1993; 87: 1052.
82. [82] Cox JL, Boineau JP, Schuessler RB et al. Electrophysiologic basis, surgical development, and clinical results of the maze procedure for atrial flutter and atrial fibrillation. Adv Card Surg 1995; 6: 1-67.
83. [83] Scherf D. Studies on auricular tachycardia caused by aconitine administration. Proc Soc Exp Biol Med 1947; 64: 233-9.
84. [84] Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation 1990; 82: 1106-16.
85. [85] Flaker GC, Blackshear JL, McBride R, Kronmal RA, Halperin JL, Hart RG. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol 1992; 20: 527-32.
86. [86] Deedwania PC, Singh BN, Fletcher R, Fisher S, Singh S. Amiodarone improves survival by restoring and maintaining sinus rhythm in patients with chronic atrial fibrillation, dilated cardiomyopathy, and congestive heart failure. Circulation 1996; 94 (Suppl I): I-667.
87. [87] Anderson JL, Gilbert EM, Alpert BL et al. Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study Group. Circulation 1989; 80: 1557-70.
88. [88] Echt DS, Liebson PR, Mitchell LB et al. Mortality and morbidity in patients receiving encainide flecainide or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324: 781-8.
89. [89] Ellenbogen KA, Stambler BS, Wood MA, Sager PT, Wesley RC, Meissner MD. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter. A dose-response study. J Am Coll Cardiol 1996; 28: 130-6.
90. [90] Boriani G, Capucci A, Lenzi T, Sanguinetti M, Magnani B. Propafenone for conversion of recent-onset atrial fibrillation. Chest 1995; 108: 355-8.
91. [91] Gallagher MM, Camm AJ. Classification of atrial fibrillation. PACE 1997; 20: 1603-5.
92. [92] de Bakker JMT, van Capelle FJL, Janse MJ et al. Slow conduction in the infarcted human heart - zigzag course of activation. Circulation 1993; 88: 915-26.
93. [93] Myerburg RJ, Kessler KM, Bassett AL, Castellanos A. A biological approach to sudden cardiac death: Structure, function and cause. Am J Cardiol 1989; 63: 1512-16.
94. [94] Myerburg RJ, Kessler KM, Castellanos A. Sudden cardiac death: Structure, function and time-dependence of risk. Circulation 1992; 85 (Suppl I): I-2-I-10.
95. [95] Myerburg RJ, Kessler KM, Castellanos A. Sudden cardiac death: Epidemiology, transient risk and intervention assessment. Ann Int Med 1993; 119: 1187-97.
96. [96] Zipes D, Mitrani R, Klein L, Miles W. Cardiac sympathetic scintigraphy. In: Zipes D, Jalife J, eds. Cardiac Electrophysiology: From Cell to Bedside. Philadelphia, PA: WB Saunders Co, 1995: 1129-33.
97. [97] Vermeulen JT, Tan HL, Rademaker CA et al. Electrophysiologic and extracellular ionic changes during acute ischemia in failing and normal rabbit myocardium. J Mol Cell Cardiol 1996; 28: 123-31.
98. [98] Schwartz PJ, Billman GE, Stone HL. Autonomic mechanisms in ventricular fibrillation induced by myocardial ischemia during exercise in dogs with a healed myocardial infarction. An experimental preparation for sudden cardiac death. Circulation 1984; 64: 790-800.
99. [99] Kleiger RE, Miller JP, Bigger JT, Moss AJ. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987; 59: 256-62.
100. [100] Huikuri HV, Linnaluoto MK, Seppanen T et al. Circadian rhythm of heart rate variability in survivors of cardiac arrest. Am J Cardiol 1992; 70: 610-5.
101. [101] Bigger Jr JT, Fleiss JL, Steinman RC, Rolnitzky LM, Kleiger RE, Rottman JN. Frequency domain measures of heart period variability and mortality after myocardial infarction. Circulation 1992; 85: 164-71.
102. [102] Kozlovskis PL, Smets MJ, Duncan RC, Bailey BK, Bassett AL, Myerburg RJ. Regional β-adrenergic receptors and adenylate cyclase activity after healing of myocardial infarction in cats. J Mol Cell Cardiol 1990; 22: 311-22.
103. [103] Aggarwal R, Boyden PA. Diminished calcium and barium currents in myocyte surviving in the epicardial border zone of the 5 day infarcted canine heart. Circ Res 1995; 77: 1180-91.
104. 2+ currents in myocytes that survive in the infarcted heart. J Cardiovasc Electrophysiol 1996; 7: 20-35.
105. [105] Steinberg SF, Zhang HL, Pak E, Pagnotta G, Boyden PA. Characteristics of the adrenergic receptor complex in the epicardial border zone of the 5 day infarcted heart. Circulation 1995; 91: 2824-33.
106. [106] de Bakker JMT, van Capelle FJL, Janse MJ et al. Reentry as a cause of ventricular tachycardia in patients with chronic ischemic heart disease: electrophysiologic and anatomic correlation. Circulation 1988; 77: 589-606.
107. [107] de Bakker JMT, Van Capelle FJL, Janse MJ et al. Macroreentry in the infarcted human heart - the mechanism of ventricular tachycardias with a focal activation pattern. J Am Coll Cardiol 1991; 18: 1005-14.
108. [108] Dillon SM, Allessie MA, Ursell PC, Wit AL. Influences of anisotropic tissue structure on reentrant circuits in the epicardial border zone of subacute canine infarcts. Circ Res 1988; 63:182-206.
109. [109] Spear JF, Michelson EL, Moore EN. Reduced space constant in slowly conducting regions of chronically infarcted myocardium. Circ Res 1983; 53: 176-85.
110. [110] Matsubara H, Suzuki J, Inada M. Shaker-related potassium channels, Kv1.4, mRNA regulation in cultured rat heart myocytes and different expression of Kv1.4 and Kv1.5 genes in myocardial development and hypertrophy. J Clin Invest 1993; 92: 1659-66.
111. [111] Mori Y, Matsubara H, Folco E, Siegel A, Koren G. The transcription of a mammalian voltage-gated potassium channel is regulated by cAMP in a cell-specific manner. J Biol Chem 1993; 268: 26482-93.
112. [112] Hirsch AT, Talsness CE, Schunkert H, Paul M, Dzau VJ. Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ Res 1991; 69: 475-82.
113. [113] Kaye D, Smith TW, Kelly RA. Role of transiently altered sarcolemmal membrane permeability and basic fibroblast growth factor release in the hypertrophic response of adult rat ventricular myocytes to increased mechanical activity in vitro. J Clin Invest 1996; 97: 281-91.
114. [114] Sadoshima J, Izumo S. Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ Res 1993; 73: 413-23.
115. max and the transient outward current. Circulation 1992; 85: 1175-88.
116. [116] Pu J, Boyden PA. Reduced sodium current density and function in myocytes from the epicardial border zone of the infarcted heart: A possible ionic mechanisms for altered excitability and post repolarization refractoriness. Circ Res 1997; 81: 1024-33.
117. [117] Boyden PA, Pinto JM. Reduced calcium currents in subendocardial Purkinje myocytes that survive in the 24-and 48-hour infarcted heart. Circulation 1994; 89: 2747-59.
118. [118] Jeck CD, Pinto JM, Boyden PA. Transient outward currents in subendocardial Purkinje myocytes surviving in the infarcted heart. Circulation 1995; 92: 465-73.
119. K) in feline left ventricular myocytes adjacent to healed myocardial infarct area (Abstr). Circulation 1995; 92: I-158: 753.
120. [120] Pinto JMB, Yuan F, Wasserlauf B, Bassett A, Myerburg R. Regional gradation of L-type calcium currents in the feline heart with a healed myocardial infarct. J Cardiovasc Electrophysiol 1997; 8: 548-60.
121. [121] Dolber PC, Beyer EC, Junker EL, Spach MS. Distribution of gap junctions in dog and rat ventricle studied with a double-label technique. J Moll Cell Cardiol 1992; 24: 1443-57.
122. [122] Saffitz JE, Kanter HL, Green GK, Tolley TK, Beyer EC. Tissue specific determinants of anisotropic conduction velocity in canine atrial and ventricular myocardium. Circ Res 1994; 74: 1065-70.
123. [123] Smith JH, Green CR, Peter NS, Rothery S, Severs NJ. Altered patterns of gap junction distribution in ischemic heart disease - an immunohistochemical study of human myocardium using laser scanning confocal microscopy. Am J Pathol 1991; 139: 801-21.
124. [124] Peters N, Coromilas J, Severs N, Wit A. Disturbed connexin43 gap junction distribution correlates with the location of recentrant circuits in the epicardial border zone of healing canine infarcts that cause ventricular tachycardia. Circulation 1997; 95: 988-96.
125. [125] Fast VG, Darrow BJ, Saffitz JE, Kleber AG. Anisotropic activation spread in heart cell monolayers assessed by high-resolution and optical mapping: role of tissue discontinuities. Circ Res 1996; 79: 115-27.
126. [126] Baker KM, Booz GW, Dostal DE. Cardiac actions of angiotensin II. Annu Rev Physiol 1992; 54: 227-41.
127. [127] Kent RL, McDermott PJ. Passive load and angiotensin II evoke differential responses of gene expression and protein synthesis in cardiac myocytes. Circ Res 1996; 78: 829-38.
128. [128] La Rovere MT, Specchia G, Mortara A, Schwartz PJ. Baroreflex sensitivity, clinical correlates, and cardiovascular mortality among patients with a first myocardial infarction: a prospective study. Circulation 1988; 78: 816-24.
129. [129] Furukawa T, Rozanski JJ, Nogami A, Moroe K, Gosselin AJ, Lister JW. Time-dependent risk of and predictors for cardiac arrest recurrence in survivors of out-of-hospital cardiac arrest with chronic artery disease. Circulation 1989; 80: 599-608.
130. [130] The BHAT research group. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 1982; 247: 1707-14.
131. [131] Hjalmarson A, Herlitz J, Malek I et al. Effect on mortality of metoprolol in acute myocardial infarction. Lancet 1981; 2: 823-7.
132. [132] Rutherford JD, Pfeffer MA, Moye LA et al. Effect of captopril on ischemic events after myocardial infarction. Circulation 1994; 90: 1731-8.
133. [133] Kober L, Torp-Pedersen C, Carlsen JE et al., the TRACE Investigators. A clinical trial of the angiotensin converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995; 333: 1670-6.
134. [134] Pitt B, Segal R, Martinez FA et al Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of losartan in the Elderly Study). Lancet 1997; 349: 747-52.
135. [135] The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
136. [136] Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with provastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7.
137. [137] The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992; 327: 227-33.
138. [138] Ceremuzynski L, Kleczar E, Krzeminska-Pakula M et al Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo-controlled pilot study. J Am Coll Cardiol 1992; 20: 1056-62.
139. [139] Burkart F, Pfisterer M, Kiowski W, Follath F, Burckhardt D. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with aysmptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). J Am Coll Cardiol 1990; 16: 1711-18.
140. [140] Pfisterer M, Kiowski W, Burckhardt D, Follath F, Burkart F. Beneficial effect of amiodarone on cardiac mortality in patients with asymptomatic complex ventricular arrhythmias after acute myocardial infarction and preserved but not impaired left ventricular function. Am J Cardiol 1992; 69: 1399-1402.
141. [141] Garguichevich JJ, Ramos JL, Gambarte A et al. Effect of amiodarone therapy on mortality in patients with left ventricular dysfunction and asymptomatic complex ventricular arrhythmias: Argentine Pilot Study of Sudden Death and Amiodarone (EPAMSA). Am Heart J 1995; 130: 494-500.
142. [142] Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R.Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevide en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet 1994; 344: 493-8.
143. [143] Singh SN, Fletcher RD, Fisher SG et al. Amiodarone in patients with congestive heart failure and aysymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med 1995; 333: 77-82.
144. [144] Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomized trials. Lancet 1997; 350: 1417-24.
145. [145] Moss AJ, Hall WJ, Cannom DS et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicentre Automatic Defibrillator Implantation in Trial Investigators. N Engl J Med 1996; 335: 1933-60.
146. [146] Spotnitz HM, Herre JM, Baker LD, Fitzgerald DM, Kron IL, Bigger Jr JT, for the Surgical Investigators. The CABG Patch Trial. Circulation 1996; 94: 248-53.
147. [147] Bardy GH, Lee KL, Mark DB et al. Sudden cardiac death in heart failure trial: pilot study. PACE 1997; 20: 1148.
148. [148] The CASCADE Investigators. Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE study). J Am Coll Cardiol 1993; 72: 280-7.
149. [149] Kleiger RE, Miller JP, Bigger JT, Moss AJ, and the Multicenter Post-infarction Research Group. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987; 59: 256-62.
150. [150] Task Force of the European Society of Cardiology and the North American Society. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Circulation 1996; 93: 1043-65.
151. [151] La Rovere MT, Mortara A, Bigger Jr JT et al. for the ATRAMI Investigators. The prognostic value of baroreflex sensitivity and heart rate variability after myocardial infarction: the ATRAMI study. Circulation 1996; 94 (Abstr Suppl): 1-19.
152. [152] Mason JW. A comparison of electrophysiologic testing with Holter monitoring to predict antiarrhythmic-drug efficacy for ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators. N Engl J Med 1993; 329: 498-9.
153. [153] Mason JW. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrythmias. Electrophysiologic Study versus Electrocardiographic Monitoring (ESVEM) Investigators. N Engl J Med 1993; 329: 452-8.
154. [154] Newman D, Sauve MJ, Herre J et al. Survival after implantation of the cardioverter defibrillator. Am J Cardiol 1992; 69: 899-903.
155. [155] Bocker D, Haverkamp W, Block M, Hammell D, Borggrefe M, Breithardt G. Comparison of d,l-sotalol and implantable defibrillators for treatment of sustained ventricular tachycardia or fibrillation in patients with coronary artery disease. Circulation 1996; 94: 151-7.
156. [156] The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997; 337: 1576-83.
157. [157] Connolly SJ, Gent M, Roberts RS, Dorian P, Green MS, Klein GJ, Mitchell LB, Sheldon RS, Roy D. Canadian implantable defibrillator study (CIDS): Study design and organization. Am J Cardiol 1993; 72: 103F-8F.
158. [158] Siebels J, Kuck KH. Implantable cardioverier defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivors (the Cardiac Arrest Study Hamburg). Am Heart J 1994; 127: 1139-44.
159. [159] Nisam S, Breithardt G. Mortality trials with implantable defibrillators. Am J Cardiol 1997; 79: 468-71.
160. [160] Bocker D, Haverkamp W, Block M, Hammel D, Borggrefe M, Breithardt G. Comparison of d,l-sotalol and implantable defibrillators for treatment of sustained ventricular tachycardia or fibrillation in patients with coronary artery disease. Circulation 1996; 94: 151-7.